-
1
-
-
0021721387
-
Leuprolide versus diethylstilbestrol for metastatic prostate cancer
-
Leuprolide Study Group
-
Garnick M.B., Glode L.M., and Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311 (1984) 1281
-
(1984)
N Engl J Med
, vol.311
, pp. 1281
-
-
Garnick, M.B.1
Glode, L.M.2
-
2
-
-
8544230666
-
Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells
-
Lee J.T., Steelman L.S., and McCubrey J.A. Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 64 (2004) 8397
-
(2004)
Cancer Res
, vol.64
, pp. 8397
-
-
Lee, J.T.1
Steelman, L.S.2
McCubrey, J.A.3
-
3
-
-
33745172528
-
The deficiency of Akt1 is sufficient to suppress tumor development in Pten mice
-
Chen M.L., Xu P.Z., Peng X.D., et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten mice. Genes Dev 20 (2006) 1569
-
(2006)
Genes Dev
, vol.20
, pp. 1569
-
-
Chen, M.L.1
Xu, P.Z.2
Peng, X.D.3
-
4
-
-
0034808673
-
HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer
-
Osman I., Scher H.I., Drobnjak M., et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7 (2001) 2643
-
(2001)
Clin Cancer Res
, vol.7
, pp. 2643
-
-
Osman, I.1
Scher, H.I.2
Drobnjak, M.3
-
5
-
-
0034833701
-
Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease
-
Shi Y., Brands F.H., Chatterjee S., et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 166 (2001) 1514
-
(2001)
J Urol
, vol.166
, pp. 1514
-
-
Shi, Y.1
Brands, F.H.2
Chatterjee, S.3
-
6
-
-
12344252767
-
Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities
-
Vashchenko N., and Abrahamsson P.A. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 47 (2005) 147
-
(2005)
Eur Urol
, vol.47
, pp. 147
-
-
Vashchenko, N.1
Abrahamsson, P.A.2
-
7
-
-
12844287338
-
Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype
-
Evangelou A.I., Winter S.F., Huss W.J., et al. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem 91 (2004) 671
-
(2004)
J Cell Biochem
, vol.91
, pp. 671
-
-
Evangelou, A.I.1
Winter, S.F.2
Huss, W.J.3
-
8
-
-
33744935016
-
Loss of PTEN is associated with progression to androgen independence
-
Bertram J., Peacock J.W., Fazli L., et al. Loss of PTEN is associated with progression to androgen independence. Prostate 66 (2006) 895
-
(2006)
Prostate
, vol.66
, pp. 895
-
-
Bertram, J.1
Peacock, J.W.2
Fazli, L.3
-
9
-
-
0032431032
-
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway
-
Wu X., Senechal K., Neshat M.S., et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95 (1998) 15587
-
(1998)
Proc Natl Acad Sci U S A
, vol.95
, pp. 15587
-
-
Wu, X.1
Senechal, K.2
Neshat, M.S.3
-
10
-
-
0031961980
-
Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor
-
Moscatello D.K., Holgado-Madruga M., Emlet D.R., et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273 (1998) 200
-
(1998)
J Biol Chem
, vol.273
, pp. 200
-
-
Moscatello, D.K.1
Holgado-Madruga, M.2
Emlet, D.R.3
-
11
-
-
33745255349
-
Androgen-dependent regulation of Her-2/neu in prostate cancer cells
-
Berger R., Lin D.I., Nieto M., et al. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 66 (2006) 5723
-
(2006)
Cancer Res
, vol.66
, pp. 5723
-
-
Berger, R.1
Lin, D.I.2
Nieto, M.3
-
12
-
-
33947538812
-
Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer
-
Wu C., and Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 282 (2007) 3571
-
(2007)
J Biol Chem
, vol.282
, pp. 3571
-
-
Wu, C.1
Huang, J.2
-
13
-
-
33847258452
-
Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer
-
Wellington K., and Keam S.J. Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer. Drugs Aging 24 (2007) 169
-
(2007)
Drugs Aging
, vol.24
, pp. 169
-
-
Wellington, K.1
Keam, S.J.2
-
14
-
-
0030890120
-
Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy
-
Reuter V.E. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49 (1997) 16
-
(1997)
Urology
, vol.49
, pp. 16
-
-
Reuter, V.E.1
-
15
-
-
0023359813
-
Cytological grading of therapy-induced tumor regression in prostatic carcinoma: proposal of a new system
-
Böcking A., and Auffermann W. Cytological grading of therapy-induced tumor regression in prostatic carcinoma: proposal of a new system. Diagn Cytopathol 3 (1987) 108
-
(1987)
Diagn Cytopathol
, vol.3
, pp. 108
-
-
Böcking, A.1
Auffermann, W.2
-
16
-
-
0022283210
-
Treated prostatic carcinoma. Histological, immunohistochemical and cell kinetic studies
-
Helpap B. Treated prostatic carcinoma. Histological, immunohistochemical and cell kinetic studies. Appl Pathol 3 (1985) 230
-
(1985)
Appl Pathol
, vol.3
, pp. 230
-
-
Helpap, B.1
-
17
-
-
35948978956
-
Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer
-
Festuccia C., Gravina G.L., Muzi P., et al. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. Endocr Relat Cancer 14 (2007) 601
-
(2007)
Endocr Relat Cancer
, vol.14
, pp. 601
-
-
Festuccia, C.1
Gravina, G.L.2
Muzi, P.3
-
18
-
-
33845908460
-
Neoadjuvant therapy before radical prostatectomy: where have we been?. Where are we going?
-
Pendleton J., Pisters L.L., Nakamura K., et al. Neoadjuvant therapy before radical prostatectomy: where have we been?. Where are we going?. Urol Oncol 25 (2007) 11
-
(2007)
Urol Oncol
, vol.25
, pp. 11
-
-
Pendleton, J.1
Pisters, L.L.2
Nakamura, K.3
-
19
-
-
23944523430
-
The emerging role of the PI3-K-Akt pathway in prostate cancer progression
-
Li L., Ittmann M.M., Ayala G., et al. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 8 (2005) 108
-
(2005)
Prostate Cancer Prostatic Dis
, vol.8
, pp. 108
-
-
Li, L.1
Ittmann, M.M.2
Ayala, G.3
-
20
-
-
27844506524
-
Akt-regulated pathways in prostate cancer
-
Majumder P.K., and Sellers W.R. Akt-regulated pathways in prostate cancer. Oncogene 24 (2005) 7465
-
(2005)
Oncogene
, vol.24
, pp. 7465
-
-
Majumder, P.K.1
Sellers, W.R.2
-
21
-
-
0036847724
-
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
-
Di Lorenzo G., Tortora G., D'Armiento F.P., et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8 (2002) 3438
-
(2002)
Clin Cancer Res
, vol.8
, pp. 3438
-
-
Di Lorenzo, G.1
Tortora, G.2
D'Armiento, F.P.3
|